News | February 08, 2010

On-Pump, Off-Pump Bypass Surgery Yield Similar Results

February 9, 2010 – Off-pump bypass surgery, or “beating heart surgery,” was developed in hopes of creating a safer way to fix cholesterol-clogged coronary arteries. But a major new study suggests that off-pump bypass surgery doesn’t quite measure up to the traditional operation, in which the heart is stopped during the procedure and a heart-lung machine pumps blood through the body, reports the February 2010 issue of the Harvard Heart Letter.

Early reports about off-pump bypass surgery indicated the operation caused less confusion and memory loss afterward, problems that were attributed to the use of the heart-lung machine. Some later, larger, and longer studies supported these findings, while others didn’t. Now, results from a large head-to-head comparison trial are bringing some clarity to the hot debate over which procedure is better.

In the trial, men and women needing bypass surgery were randomly assigned to the on-pump or off-pump operation. At 30 days after the procedure, the results were almost identical — similar numbers of deaths, strokes, and cardiac arrests. One key difference was that 18 percent of the off-pump group ended up getting fewer grafts than planned, compared with 11 percent of the on-pump group. A year later, 9.9 percent of the participants in the off-pump group had died, had a heart attack, or needed another procedure, compared with 7.4 percent in the on-pump group. And participants in both groups scored the same on tests designed to assess memory and thinking skills.

The Harvard Heart Letter notes that off-pump surgery clearly isn’t better than traditional bypass surgery, and on-pump bypass sometimes yields a better or more durable fix. The skill and experience of the surgeon and operating team are probably more important than the type of bypass surgery performed.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Overlay Init